IL117998A - Use of leukemia inhibitory factor and endothelin antagonists in the manufacture of a medicament - Google Patents

Use of leukemia inhibitory factor and endothelin antagonists in the manufacture of a medicament

Info

Publication number
IL117998A
IL117998A IL11799896A IL11799896A IL117998A IL 117998 A IL117998 A IL 117998A IL 11799896 A IL11799896 A IL 11799896A IL 11799896 A IL11799896 A IL 11799896A IL 117998 A IL117998 A IL 117998A
Authority
IL
Israel
Prior art keywords
antagonist
antibody
lif
endothelin
antibodies
Prior art date
Application number
IL11799896A
Other languages
English (en)
Other versions
IL117998A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL117998A0 publication Critical patent/IL117998A0/xx
Publication of IL117998A publication Critical patent/IL117998A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL11799896A 1995-04-24 1996-04-22 Use of leukemia inhibitory factor and endothelin antagonists in the manufacture of a medicament IL117998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24

Publications (2)

Publication Number Publication Date
IL117998A0 IL117998A0 (en) 1996-08-04
IL117998A true IL117998A (en) 2001-04-30

Family

ID=23694642

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11799896A IL117998A (en) 1995-04-24 1996-04-22 Use of leukemia inhibitory factor and endothelin antagonists in the manufacture of a medicament

Country Status (12)

Country Link
EP (2) EP1287832B1 (fr)
JP (1) JPH11504332A (fr)
AT (2) ATE233570T1 (fr)
AU (1) AU702375B2 (fr)
CA (1) CA2214636C (fr)
DE (2) DE69635630T2 (fr)
DK (2) DK0830143T3 (fr)
ES (1) ES2254564T3 (fr)
IL (1) IL117998A (fr)
MX (1) MX9707939A (fr)
WO (1) WO1996033740A1 (fr)
ZA (1) ZA963274B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001404A1 (fr) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services COMPOSITIONS ET PROCEDES DE FECONDATION $i(IN VITRO)
EP1549198A4 (fr) * 2002-09-30 2007-03-28 Univ Duke Atrophie thymique
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (fr) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Anticorps reconnaissant le facteur d'inhibition de la leucémie humaine (LIF) et utilisation d'anticorps anti-LIF pour le traitement de maladies associées à la prolifération de cellules indésirables
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (fr) * 1993-09-24 1995-03-30 Abbott Laboratories Antagonistes d'endotheline

Also Published As

Publication number Publication date
AU702375B2 (en) 1999-02-18
CA2214636C (fr) 2009-12-22
EP1287832A3 (fr) 2003-04-16
EP0830143B1 (fr) 2003-03-05
EP0830143A1 (fr) 1998-03-25
DE69626510D1 (de) 2003-04-10
ZA963274B (en) 1997-10-24
WO1996033740A1 (fr) 1996-10-31
MX9707939A (es) 1997-12-31
JPH11504332A (ja) 1999-04-20
DE69635630D1 (de) 2006-01-26
ATE233570T1 (de) 2003-03-15
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
DK0830143T3 (da) 2003-06-16
EP1287832A2 (fr) 2003-03-05
CA2214636A1 (fr) 1996-10-31
IL117998A0 (en) 1996-08-04
ES2254564T3 (es) 2006-06-16
EP1287832B1 (fr) 2005-12-21
ATE313333T1 (de) 2006-01-15
DE69626510T2 (de) 2003-12-11
AU5665896A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
US6156733A (en) Use of leukemia inhibitory factor and endothelin antagonists
US5627073A (en) Hybridomas producing antibodies to cardiac hypertrophy factor
US5534615A (en) Cardiac hypertrophy factor and uses therefor
US5635388A (en) Agonist antibodies against the flk2/flt3 receptor and uses thereof
US7696321B2 (en) Molecules and methods for inhibiting shedding of KIM-1
EP2091563B1 (fr) Neutralisation d'anticorps monoclonaux contre le récepteur nogo-66 (ngr) et leurs utilisations
US7332161B2 (en) Treatment of disease with antibodies against high molecular weight kininogen domain 5
US20020143150A1 (en) Monoclonal antibody to the clonotypic structure of a T-cell receptor, a pharmaceutical composition and a diagnostic reagent comprising the same
CN102089327A (zh) 抗PirB抗体
EP0830143B1 (fr) Utilisation d'antagonistes du facteur d'inhibition de la leucemie et de l'endotheline
US20140135483A1 (en) Soluble integrin alpha-4 mutant
US20060153840A1 (en) Methods for preventing or treating a condition or a disease associated with angiogenesis
Sithigorngul et al. Generation of monoclonal antibodies against a nematode peptide extract: another approach for identifying unknown neuropeptides
WO2001058526A2 (fr) Melanges d'inhibiteurs de caspase et d'inhibiteurs de complement et leurs methodes d'utilisation
US20060088501A1 (en) Duffy antigen receptor for chemokines and use thereof
US7148063B2 (en) Mitochondrial creatine kinase antibody
US20070014799A1 (en) Antibody and use of the same
Watters et al. Monoclonal antibody that inhibits biological activity of a mammalian ciliary neurotrophic factor
WO2001034195A1 (fr) Inhibition de l'angiogenese par des anticorps avec du kininogene de haut poids moleculaire du domaine 5
CA2489780A1 (fr) Methodes de prevention ou de traitement d'un etat pathologique lie a l'angiogenese
US20060051344A1 (en) Antibody and utilization of the same
HK1195249A (en) Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
MX2007004843A (es) Receptor de antigeno duffy para quimocinas y uso del mismo

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees